Journal of Pharmacokinetics & Experimental Therapeutics
Open Access

Patient stratification is a critical concept in modern healthcare, where treatment approaches are tailored based on a patient's unique characteristics. This strategy is aimed at improving outcomes by ensuring that patients receive the most effective therapies suited to their individual profiles. It is particularly relevant in the fields of precision medicine, pharmacogenomics, and clinical pharmacology. By dividing patients into subgroups based on factors such as genetics, disease severity, biomarkers, and response to previous treatments, stratification allows clinicians to optimize treatment plans, reduce adverse effects, and achieve better health outcomes. This article explores the principles, methods, and clinical significance of patient stratification, particularly in the context of chronic diseases, cancer, and pharmacology [1].

Methodology

Patient stratification involves categorizing individuals into subgroups based on shared characteristics to tailor treatment approaches and optimize clinical outcomes. The methodology of patient stratification typically includes several steps, incorporating various data sources and technologies.

Data collection: The first step in stratification is gathering comprehensive patient data, including clinical history, demographics, disease severity, lifestyle factors, and lab results. This data provides the foundation for identifying relevant factors that may influence treatment response [2].

Genetic and molecular profiling: One of the most advanced methods in patient stratification is the use of genomic testing to identify genetic variants, polymorphisms, or mutations that may affect drug metabolism or disease progression. Next-generation sequencing (NGS) or whole genome sequencing (WGS) can be used to analyze the genetic makeup of individuals, allowing for the identification of personalized treatment approaches based on these genetic insights [3 ]. This is especially critical in diseases such as cancer, where tumor genetic profiling helps in selecting targeted therapies.

Biomarker analysis: Biomarkers are measurable indicators of disease presence or progression. Identifying biomarkers through blood tests, imaging, or tissue samples helps in stratifying patients for specific therapies. For example, in cancer, markers like HER2 or EGFR mutations guide the selection of targeted treatments like trastuzumab or gefitinib.

Clinical risk scoring: In many chronic diseases, risk scoring models are used to assess the likelihood of adverse outcomes based on factors like age, comorbidities, and disease progression. For instance, risk calculators for heart disease or diabetes can help identify high-risk patients who may benefit from aggressive treatment [4 ].

Artificial intelligence and machine learning: These technologies analyze large datasets to predict how different patient groups will respond to therapies. By integrating clinical data, genetic information, and lifestyle factors, AI tools can assist in refining patient stratification and treatment decisions.

Understanding patient stratification

Patient stratification involves categorizing individuals into distinct groups that share common characteristics, such as genetic profiles, risk factors, and clinical history. The goal is to understand how different subpopulations will respond to specific treatments or interventions. Stratification helps address the "one-size-fits-all" approach that often fails to account for the diversity of patient responses. For instance, while some patients may respond favorably to a particular medication, others may experience severe side effects or even treatment failure.

Stratifying patients allows for personalized medicine, where treatments are more effectively aligned with the patient’s genetic makeup, lifestyle, and disease characteristics. In doing so, it ensures that the right patients receive the right drug at the right time and in the appropriate dosage [5-6-7].

Clinical applications of patient stratification

The practical application of patient stratification can be seen across various therapeutic areas:

Cancer treatment: In oncology, patient stratification is critical for determining the most effective treatment regimen. Through molecular profiling of tumors, doctors can identify specific genetic mutations or alterations in the cancer cells that make them sensitive to particular therapies. For example, patients with HER2-positive breast cancer may benefit from trastuzumab (Herceptin), while those with other breast cancer subtypes may require different therapies [8,9]. Personalized cancer therapies allow for better-targeted treatments and the avoidance of unnecessary side effects from ineffective treatments.

Chronic Diseases: For chronic conditions like hypertension, diabetes, and obesity, patient stratification helps identify the most appropriate treatment approach. For instance, certain hypertensive patients may respond better to ACE inhibitors, while others may have a more favorable response to calcium channel blockers. Understanding a patient’s underlying genetic predisposition and medical history can lead to better control of these diseases and the prevention of complications.

Cardiovascular medicine: Stratification also plays a significant role in the management of cardiovascular diseases. In patients with coronary artery disease (CAD) or those at high risk for heart attacks, genetic screening and lipid profiling can guide clinicians in prescribing statins or antiplatelet therapies more effectively. For example, some individuals may require higher doses of statins to achieve adequate lipid lowering, while others may need different medications due to poor statin response or side effects.

Pharmacological approaches: In pharmacology, patient stratification enables healthcare providers to make informed decisions regarding drug selection and dosing. For example, in the case of antidepressants, genetic variations in drug-metabolizing enzymes can determine how effectively a patient processes certain medications. Stratified dosing ensures that patients receive the optimal amount of medication, reducing the risk of both under-dosing and overdosing [10].

Conclusion

Patient stratification is transforming the way healthcare providers approach diagnosis and treatment. By considering genetic, clinical, and environmental factors, stratification enables more personalized treatment plans, improving therapeutic efficacy and minimizing unnecessary side effects. As technology continues to evolve, the integration of genomic data, biomarkers, and AI-based tools will further refine the process of patient stratification, enabling better-targeted therapies across a range of diseases. While there are challenges in implementing this approach, patient stratification holds immense potential in revolutionizing healthcare and ensuring that treatments are optimized for the individual.

1. Atkinson AJ, Lalonde RL (2007) Introduction of Quantitative Methods in Pharmacology and Clinical Pharmacology: A Historical Overview. Clin Pharmacol Ther 82: 3-6.

Indexed at, Google Scholar, Crossref

2. Mould DR, Upton RN (2012) Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development. CPT Pharmacometrics Syst Pharmacol 1: 6.

Indexed at, Google Scholar, Crossref

3. Aarons L (2005) Physiologically Based Pharmacokinetic Modelling: A Sound Mechanistic Basis Is Needed. Br J Clin Pharmacol 60: 581-583.

Indexed at, Google Scholar, Crossref

4. Dhillon S, Gill K (2006) Clinical Pharmacokinetic. Pharmaceutical Press, London.

 Google Scholar

5. Cawello W, Rosenkranz B, Schmid B (2013) Pharmacodynamic and Pharmacokinetic Evaluation of Coadministration of Lacosamide and an Oral Contraceptive (Levonorgestrel Plus Ethinylestradiol) in Healthy Female Volunteers. Epilepsia 54: 530-536.

Indexed at, Google Scholar, Crossref

6. Ben‐Menachem E, Dominguez J, Szasz J, Beller C, Howerton C, et al. (2021) Long‐term safety and tolerability of lacosamide monotherapy in patients with epilepsy: Results from a multicenter, open‐label trial. Epilepsia 6: 618-623.

Indexed at, Google Scholar, Crossref

7. Ferreira JA, Le Pichon JB, Abdelmoity AT, Dilley D, Dedeken P, et al. (2019) Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures-An open-label trial. Seizure 71: 166-173.

Indexed at, Google Scholar, Crossref

8. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, et al. (2007) Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48: 1308-1317.

Indexed at, Google Scholar, Crossref

9. Chung S, Sperling MR, Biton V, Krauss G, Hebert D, et al. (2010) Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 51: 958-967.

Indexed at, Google Scholar, Crossref

10. Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, Rosenow F, Doty P, et al. (2009) Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 50: 443-453.

Indexed at, Google Scholar, Crossref